背景:口服水溶性造影剂(WSC)可以追踪小肠梗阻(SBO)的消退,但没有普遍的使用途径。我们制定并实施了基于证据的指南,用于WSC在胶粘剂SBO管理中的使用,在多伦多大学附属医院实施。
方法:我们进行了系统评价,并制定了WSC在粘合剂SBO治疗中的临床实践指南。该指南经专家小组协商一致批准,并于2018年实施。我们在1个试点地点(大型学术三级护理中心)进行了指南实施的前瞻性队列研究,由中心的急诊普外科服务提供便利。主要结果包括遵守指南和住院时间(LOS)。次要结果包括非手术治疗的失败率,发病率,1年内SBO复发的死亡率和再入院。2016年收治的粘连性SBO患者作为对照队列。
结果:我们分析了该中心收治的152例粘连性SBO患者的数据,2016年为65岁(历史队列),2018年1月至6月为56(过渡队列),2018年7月至12月为31(实施队列)。2018年,WSC方案的依从性显着增加,接受WSC的患者比例从过渡队列中的45%(n=25)增加到实施队列中的71%(n=22)(p<0.001)。队列中的中位LOS没有差异(p=0.06)。过渡和实施队列的再入院率明显较低(13[23%]和9[29%],分别)高于历史队列(29[45%])(p=0.04)。在最初被分配到非手术治疗的患者中,接受WSC的人比没有接受WSC的人继续接受手术的比例高得多(14.6%对3.6%,p=0.01),中位手术时间无差异(p=0.2)。
结论:成功制定并实施了WSC用于SBO管理的循证指南;实施后,LOS或手术时间没有差异,但立即手术率增加,再入院率下降。我们的经验表明,通过多学科的努力和协调,实施循证临床实践指南是可行的。
BACKGROUND: Orally administered water-soluble contrast (WSC) can track resolution of small-bowel obstruction (SBO), but no universal pathway for its use exists. We developed and implemented an evidence-based
guideline for the use of WSC in the management of adhesive SBO, to be implemented across hospitals affiliated with the University of Toronto.
METHODS: We performed a systematic review and created a clinical practice
guideline for WSC use in the management of adhesive SBO. The
guideline was approved through
consensus by an expert panel and implemented in 2018. We performed a prospective cohort study of
guideline implementation at 1 pilot site (a large academic tertiary care centre), facilitated by the centre\'s acute care general surgery service. Primary outcomes included compliance with the
guideline and hospital length of stay (LOS). Secondary outcomes included rates of failure of nonoperative management, morbidity, mortality and readmission for recurrence of SBO within 1 year. Patients with adhesive SBO admitted in 2016 served as a control cohort.
RESULTS: We analyzed the data for 152 patients with adhesive SBO admitted to the centre, 65 in 2016 (historical cohort), 56 in January-June 2018 (transitional cohort) and 31 in July-December 2018 (implementation cohort). There was a significant increase in compliance with the WSC protocol in 2018, with the proportion of patients receiving WSC increasing from 45% (n = 25) in the transitional cohort to 71% (n = 22) in the implementation cohort (p < 0.001). The median LOS did not differ across the cohorts (p = 0.06). There was a significantly lower readmission rate in the transitional and implementation cohorts (13 [23%] and 9 [29%], respectively) than in the historical cohort (29 [45%]) (p = 0.04). Among patients assigned to nonoperative management initially, a significantly higher proportion of those who received WSC than those who did not receive WSC went on to undergo surgery (14.6% v. 3.6%, p = 0.01), with no difference in median time to surgery (p = 0.2).
CONCLUSIONS: An evidence-based guideline for WSC use in SBO management was successfully developed and implemented; no difference in LOS or time to surgery was seen after implementation, but rates of immediate operation increased and readmission rates decreased. Our experience shows that implementation of an evidence-based clinical practice guideline is feasible through multidisciplinary efforts and coordination.